Abstract
M
The journal expanded tremendously during the tenure of Prof. Tomasz from a quarterly journal (4 issues) to a monthly journal (12 issues in 2022). One of the visible changes has been the creation of at least one special issue per year on a hot topic. In 2023, we had our special issue on “Mycobacterial Cell-Envelope as a Target for Drug Development,” edited by Kevin Pethe (Nanyang Technological University, Singapore) and Michael Berney (Albert Einstein College of Medicine, New York), which contributed to the visibility of Microbial Drug Resistance.
Furthermore, Microbial Drug Resistance had a strong publication track record in the field of microbial drug resistance (MDR) infections associated with the COVID-19 pandemic (e.g., “Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience” and “The Spectrum of Antibiotic Prescribing During COVID-19 Pandemic: A Systematic Literature Review”) and in clinical microbiology (e.g., “Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials”).
Similarly, some editorial changes have been implemented in 2022–2023. We have updated the types of articles we consider for publication. In addition to the traditional original research articles, review articles, and letters to the editor, we now also encourage authors to submit short reports and opinion pieces, commentaries, and perspectives. We have also decided that Microbial Drug Resistance will no longer consider submissions on meta-analyses unless invited by the editors. Similarly, we strongly suggest future authors of review articles to pre-enquire with the Editor-in-Chief and Deputy Editor on the suitability for the journal, as we aim to have most of our review articles to be on invitation by the editors.
Year 2024 will be an important landmark in the journal's life as we will be celebrating its 30th anniversary. The journal Microbial Drug Resistance has been a privileged partner of the cell wall community. Former Editor-in-Chief, Alexander Tomasz, a leader in the cell wall and antibiotic field, co-organized a seminal cell wall meeting that occurred in Lago di Garda, Italy. Many participants of the meeting contributed to the special issue in 1995, gracing the field with many landmark articles.
When the Great Wall Symposium (GWS) was created in 2011 after the 2010 Baeza meeting “The Dynamics of Peptidoglycan Structure and Function: New Insights into the Great Wall” organized by Miguel de Pedro, Joe Dillard and Margaret Mcfall-Ngai, Prof. Tomasz suggested to have a special issue of the GWS in Microbial Drug Resistance. Together with the Deputy Editor, Professor David Roper, we are planning a special issue including original work and reviews related to GWS2023, a meeting that will be sponsored by European Molecular Biology Organization for the first time. Submission of articles will open in September 2023 for a publication of the special issue first semester of 2024.
Finally, I express my thanks to the editorial board and all the reviewers for their invaluable work in evaluating the scientific quality of submitted articles. But above all, let me say that Microbial Drug Resistance is only possible because of the work performed by all the contributing authors.
We continually seek out the best articles on MDR from around the world, and, therefore, invite you and your colleagues to submit your articles for publication in the journal and to ensure everyone in your institution has access by recommending the journal to your library if it is not already in their collection. The journal is indexed in PubMed/MEDLINE, PubMed Central, Current Contents®/Life Sciences and Current Contents®/Clinical Medicine, Scopus, and Web of Science: Science Citation Index® and Web of Science: Social Sciences Citation Index™. Titles and abstracts are also available on Pubmed beginning with year 2000 onward.
Sincerely yours,
—Ivo G. Boneca
Editor-in-Chief
—David Roper
Deputy Editor
—Taylor Bowen
Managing Editor